Plain-English translation of NCT07137871 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing a new drug called in people with metastatic (advanced) hormone-receptor-positive breast cancer whose cancer has continued to grow despite treatment with a CDK 4/6 inhibitor and hormone therapy. Researchers want to see whether adding this medication to your existing treatment plan can help control the cancer and understand how safe it is. This is an early-stage trial (Phase 1) with about 35 participants.
Some patients' cancers continue to grow even when treated with current standard medications like CDK 4/6 inhibitors and hormone therapy. This trial is testing whether this new medication could offer another option for people in that situation.
You likely qualify if…
You likely don't qualify if…
You will take the new medication as part of your regular treatment, with each cycle lasting 28 days. Throughout the study, you'll visit the clinic for examinations and blood tests to monitor your health and how you're responding. Every two cycles (8 weeks), you'll have CT scans of your chest, abdomen, and pelvis to measure how your tumors are responding. The researchers will track both how well the treatment works and any side effects you experience.
AI-generated summary from trial data · Nov 13, 2026 · Not medical advice
United States